Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival? [0.03%]
瑞博西利在转移性乳腺癌患者中的真实世界疗效：剂量影响生存吗？
Cristina Fernández-Cuerva,Teresa Chinchilla-Alarcón,Juan José Alcaraz-Sánchez
Cristina Fernández-Cuerva
Introduction: Real-world data are critical to demonstrate the reproducibility of evidence and external generalizability of randomized clinical trials. The purpose of this study was to assess real-world security profile and management of adv...
Outpatient initiation of venetoclax in patients with acute myeloid leukemia [0.03%]
急性髓系白血病门诊患者维奈托克的早期治疗
Shannon Palmer,Anand Patel,Christopher Wang et al.
Shannon Palmer et al.
Introduction: Venetoclax is a treatment option in patients with acute myeloid leukemia (AML) in both the front-line and relapsed/refractory settings. Initiation of therapy has been previously restricted to the inpatient s...
Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series [0.03%]
在具有严重化疗毒性的小儿肿瘤患者中发现的基因变异：病例系列报告
E C Bernsen,L M Hanff,L M Haveman et al.
E C Bernsen et al.
Paediatric oncology patients who develop severe chemotherapy-induced toxicity that requires dose reduction, delay or termination of treatment are at risk of decreased treatment efficacy. Previous research has provided evidence that genetic ...
Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting [0.03%]
在临床试验中，将西妥昔单抗作为接受双特异性抗体患者的细胞因子释放综合征的主要治疗药物
Brea C Lipe,Thomas Renaud
Brea C Lipe
Introduction: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common toxicities associated with immunotherapies, including T cell redirecting bispecific antibodies. A...
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma [0.03%]
利妥昔单抗所致脾边缘区淋巴瘤患者出现严重的急性血小板减少症
Taha Ulutan Kars,Zahit Furkan Yorgancı,Osman Yaşkıran et al.
Taha Ulutan Kars et al.
Introduction: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Ri...
Jasmin Hundal,Aditi Singh,Megan K Pereira et al.
Jasmin Hundal et al.
Introduction: Glioblastoma multiforme is the most common and aggressive type of central nervous system tumor. We present a novel case of the challenges of dosing temozolomide in a patient with end stage renal disease on p...
Predictors of community pharmacists' readiness to manage the effective and safe use of oral anticancer medicines in a developing setting [0.03%]
在发展中国家预测社区药剂师管理口服抗癌药物的有效和安全使用的准备情况的因素
Sara Dahmani,Emelith Florendo Cerbito,Anas Hamad et al.
Sara Dahmani et al.
Background: There is a paucity of studies about the readiness of community pharmacists to manage the safe and effective use of oral anticancer medicines (OAMs) in developing settings. ...
A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin [0.03%]
组织因子抗体药物偶联物Tisotumab vedotin的近期研究综述
Kevin Luu,Angelyne Chu,Brandon Chang
Kevin Luu
Objective: To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody-drug conjugate, tisotumab vedotin. Data source...
Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis [0.03%]
接受中等细胞色素P450 3A4抑制剂抗真菌预防治疗的造血细胞移植受者莱特莫韦与他克莫司相互作用影响研究
Jack Malespini,Matthew Lei,Erica Tavares et al.
Jack Malespini et al.
Introduction: Letermovir inhibits cytomegalovirus replication and is approved for the prevention of cytomegalovirus infection in cytomegalovirus seropositive hematopoietic cell transplantation recipients. Studies have fou...
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib [0.03%]
达克替尼通过抑制CYP2D6与美托洛尔相互作用引起急性肝脏损伤
Xuejia Qiu,Bingnan Ren,Yufei Lian et al.
Xuejia Qiu et al.
Introduction: In recent years, oral antineoplastic agents are commonly used in antitumor therapy. The interaction between drugs may affect the efficacy of drugs or lead to adverse reactions. We describe the case of a pati...